Investors

Overview

Overview

Corporate Profile

Nkarta is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies to treat cancer. Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.
NKX019 Clinical Update Presentation - December 2022
More information is coming soon.
NKX101 and NKX019 Initial Clinical Data Presentation – April 2022

Data Provided by Refinitiv. Minimum 15 minutes delayed.